Expression and clinical significance of p73 in Wilms' tumor in children

Ding,Yan; Guo,Xiaohui; Liu,Xinxin; Li,Jitao; Li,Ning; Xu,Cong

doi:10.3892/ol.2019.10249

Expression and clinical significance of p73 in Wilms' tumor in children

Authors:
- Yan Ding
- Xiaohui Guo
- Xinxin Liu
- Jitao Li
- Ning Li
- Cong Xu
View Affiliations

Affiliations: Department of Pediatrics (II), People's Hospital of Rizhao, Rizhao, Shandong 276800, P.R. China, Department of Child Health Care, The Third People's Hospital of Linyi, Linyi, Shandong 276000, P.R. China, Department of Spine Surgery, The Affiliated Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, Shandong 266001, P.R. China, Electrocardiogram Room, The People's Hospital of Zhangqiu Area, Jinan, Shandong 250200, P.R. China, Department of Pathology, The People's Hospital of Zhangqiu Area, Jinan, Shandong 250200, P.R. China
Published online on: April 15, 2019 https://doi.org/10.3892/ol.2019.10249
Pages: 5435-5440
Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression and clinical significance of p73 in children with Wilms' tumor (WT) were investigated. A retrospective analysis was carried out on 50 children diagnosed with WT in the People's Hospital of Rizhao, from July 2013 to January 2015 (study group), and 20 healthy children with similar age and sex who received health examinations in the same hospital during the same period (control group). The relative expression of p73 mRNA in the peripheral blood of each group was detected by reverse transcription‑quantitative PCR (RT‑qPCR) in order to study the association between p73 and the clinicopathological parameters of WT, as well as the impact of p73 on the patient prognosis. The two groups were not statistically different in respect to the clinical data of patients (P>0.05); the expression level of p73 in the blood samples of the study group was significantly higher than that of the control group (t=11.44, P<0.01); the expression of p73 in the study group was associated with factors, including tumor size, pathological type and lymphatic metastasis. Considering the mean value of the expression of p73 (3.32) as the boundary, the patients with expression value of p73 <3.32 were studied as the low‑expression group, and patients with expression value of p73 >3.32 comprised the high‑expression group. At the end of the follow‑up, the median survival time and the survival rate of the patients in the high‑expression group were significantly lower than those of the low‑expression group (P<0.05). The high expression of p73 in the peripheral blood of children with WT was positively correlated with the clinical stage of the tumor, and was closely related with the low survival rate of patients.

View Figures

View References

1	Saltzman AF, Carrasco A Jr, Weinman J, Meyers ML and Cost NG: Initial imaging for pediatric renal tumors: An opportunity for improvement. J Urol. 199:1330–1336. 2018. View Article : Google Scholar : PubMed/NCBI
2	Bozlu G and Çıtak EÇ: Evaluation of renal tumors in children. Turk J Urol. 44:268–273. 2018. View Article : Google Scholar : PubMed/NCBI
3	Tian F, Yourek G, Shi X and Yang Y: The development of Wilms tumor: From WT1 and microRNA to animal models. Biochim Biophys Acta. 1846:180–187. 2014.PubMed/NCBI
4	Zhang Y, Young A, Zhang J and Chen X: P73 tumor suppressor and its targets, p21 and PUMA, are required for Madin-Darby canine kidney cell morphogenesis by maintaining an appropriate level of epithelial to mesenchymal transition. Oncotarget. 6:13994–14004. 2015.PubMed/NCBI
5	Kurian JJ, Jehangir S and Korula A: Multiloculated cystic renal tumors of childhood: Has the final word been spoken? J Indian Assoc Pediatr Surg. 23:22–26. 2018. View Article : Google Scholar : PubMed/NCBI
6	Cutruzzolà F, Avigliano L and Candi E: p73 keeps metabolic control in balance. Cell Cycle. 13:179–180. 2014. View Article : Google Scholar : PubMed/NCBI
7	Killick R, Niklison-Chirou M, Tomasini R, Bano D, Rufini A, Grespi F, Velletri T, Tucci P, Sayan BS, Conforti F, et al: p73: A multifunctional protein in neurobiology. Mol Neurobiol. 43:139–146. 2011. View Article : Google Scholar : PubMed/NCBI
8	Inoue S, Tomasini R, Rufini A, Elia AJ, Agostini M, Amelio I, Cescon D, Dinsdale D, Zhou L, Harris IS, et al: TAp73 is required for spermatogenesis and the maintenance of male fertility. Proc Natl Acad Sci USA. 111:1843–1848. 2014. View Article : Google Scholar : PubMed/NCBI
9	Ye B, Wang X, Yang Z, Sun Z, Zhang R, Hu Y, Lu Y and Du J: p53 and p73 expression in esophageal carcinoma correlate with clinicopathology of tumors. Hepatogastroenterology. 59:2192–2195. 2012.PubMed/NCBI
10	Arisawa A, Watanabe Y, Tanaka H, Takahashi H, Matsuo C, Fujiwara T, Fujiwara M, Fujimoto Y and Tomiyama N: Comparative study of pulsed-continuous arterial spin labeling and dynamic susceptibility contrast imaging by histogram analysis in evaluation of glial tumors. Neuroradiology. 60:599–608. 2018. View Article : Google Scholar : PubMed/NCBI
11	Moll UM and Slade N: p63 and p73: roles in development and tumor formation. Mol Cancer Res. 2:371–386. 2004.PubMed/NCBI
12	Mancini P, Angeloni A, Risi E, Orsi E and Mezi S: Standard of care and promising new agents for triple-negative metastatic breast cancer. Cancers (Basel). 6:2187–2223. 2014. View Article : Google Scholar : PubMed/NCBI
13	Murphy AJ, Pierce J, de Caestecker C, Taylor C, Anderson JR, Perantoni AO, de Caestecker MP and Lovvorn HN III: SIX2 and CITED1, markers of nephronic progenitor self-renewal, remain active in primitive elements of Wilms tumor. J Pediatr Surg. 47:1239–1249. 2012. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Ishibashi K, Haber T, Breuksch I, Gebhard S, Sugino T, Kubo H, Hata J, Koguchi T, Yabe M, Kataoka M, et al: Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade. Oncotarget. 8:55230–55245. 2017. View Article : Google Scholar : PubMed/NCBI
16	Cutruzzula P, Cahn D, Kivlin D, Tong C, Edwards D and Amster M: A review of translocation t(6;11) renal cell carcinoma tumors in the adult patient. Curr Urol. 10:69–71. 2017. View Article : Google Scholar : PubMed/NCBI
17	Schultz KAP, Rednam SP, Kamihara J, Doros L, Achatz MI, Wasserman JD, Diller LR, Brugières L, Druker H, Schneider KA, et al: Pten, dicer1, fh, and their associated tumor susceptibility syndromes: Clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res. 23:e76–e82. 2017. View Article : Google Scholar : PubMed/NCBI
18	Al-Hussain T, Ali A and Akhtar M: Wilms tumor: An update. Adv Anat Pathol. 21:166–173. 2014. View Article : Google Scholar : PubMed/NCBI
19	Zitzmann F, Mayr D, Berger M, Stehr M, von Schweinitz D, Kappler R and Hubertus J: Frequent hypermethylation of a CTCF binding site influences Wilms tumor 1 expression in Wilms tumors. Oncol Rep. 31:1871–1876. 2014. View Article : Google Scholar : PubMed/NCBI
20	Franken J, Lerut E, Van Poppel H and Bogaert G: p53 immunohistochemistry expression in Wilms tumor: A prognostic tool in the detection of tumor aggressiveness. J Urol. 189:664–670. 2013. View Article : Google Scholar : PubMed/NCBI
21	Melino G, De Laurenzi V and Vousden KH: p73: Friend or foe in tumorigenesis. Nat Rev Cancer. 2:605–615. 2002. View Article : Google Scholar : PubMed/NCBI
22	Song DJ, Yue LF, Zhang D, Yang HY, Fan YX, Yue M, Pei H and Wang JX: Relationship between mRNA expression and promoter methylation status of p73 gene in peripheral blood among children with Wilms' tumor. Zhongguo Dang Dai Er Ke Za Zhi. 15:638–643. 2013.(In Chinese). PubMed/NCBI
23	McKeon F and Melino G: Fog of war: The emerging p53 family. Cell Cycle. 6:229–232. 2007. View Article : Google Scholar : PubMed/NCBI
24	Ozono E, Komori H, Iwanaga R, Tanaka T, Sakae T, Kitamura H, Yamaoka S and Ohtani K: Tumor suppressor TAp73 gene specifically responds to deregulated E2F activity in human normal fibroblasts. Genes Cells. 17:660–672. 2012. View Article : Google Scholar : PubMed/NCBI
25	Fuchs J: Surgical concepts in the treatment of Wilms tumor: An update. Urologe A. 54:1784–1791. 2015.(In German). View Article : Google Scholar : PubMed/NCBI
26	Al-Daghmin A, Alhamss S, Al-Qasem K, Al-Najjar H, Al-Smadi K, Olaimat A and Al-Halbouni L: Patterns of management of translocation renal cell carcinoma. Turk J Urol. 44:467–472. 2018. View Article : Google Scholar : PubMed/NCBI
27	Pan X, Quan J, Zhao L, Li W, Wei B, Yang S and Lai Y: Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion: A case report. Mol Clin Oncol. 8:83–85. 2018.PubMed/NCBI
28	Yong M, Yang L, Suyila Q, Han W, Yuan H, Zhao C and Su X: Expression and clinical implications of P53, P63, and P73 protein in malignant tumor of the parotid gland. Turk J Med Sci. 44:875–882. 2014. View Article : Google Scholar : PubMed/NCBI
29	Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T and Ikawa S: Possible oncogenic potential of DeltaNp73: A newly identified isoform of human p73. Cancer Res. 62:636–641. 2002.PubMed/NCBI
30	Inoue K and Fry EA: Alterations of p63 and p73 in human cancers. Subcell Biochem. 85:17–40. 2014. View Article : Google Scholar : PubMed/NCBI